Cancer subclonal genetic architecture as a key to personalized medicine.

摘要: The future of personalized oncological therapy will likely rely on evidence-based medicine to integrate all the available evidence delineate most efficacious treatment option for patient. To undertake through use targeted regimens, identification specific underlying causative mutation(s) driving growth and progression a patient's tumor is imperative. Although molecular subtyping important planning treatment, intraclonal genetic diversity has been recently highlighted as having significant implications biopsy-based prognosis. Overall, delineation clonal architecture cancer how this impact selection remain topic intense interest.